These job announcements are intended to highlight some of the hiring news over the past month and are not intended to be comprehensive. If you’d like to share job listings or announcements on our website, please contact Winnie Liu at this email: [email protected].
The Biden administration appointed Dr. Ashish Jha, dean of Brown University’s School of Public Health, to serve as the next White House Covid-19 response coordinator. He replaces Jeffrey Zients, who has served in the role since Joe Biden began his presidency. The appointment begins April 5. For more information, click here.
Norman “Ned” Sharpless MD is stepping down from his position as director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he has held since 2017. Sharpless will continue as NCI director through April 29, 2022, to ease the transition. NCI Principal Deputy Director Douglas Lowy MD will serve as NCI’s acting director effective April 30, 2022. For more information, click here.
Novartis has made some changes to its executive committee:
- Marie-France Tschudin has been appointed President, Innovative Medicines International and Chief Commercial Officer
- Victor Bulto has been appointed President, Innovative Medicines U.S.
- Steffen Lang, PhD, has been appointed President, Operations
- Shreeram Aradhye MD has been appointed President, Global Drug Development and Chief Medical Officer
- Among Novartis departures are:
- Susanne Schaffert PhD President, Novartis Oncology
- Robert Weltevreden, President, Customer & Technology Solutions
- John Tsai MD President, Global Drug Development and Chief Medical Officer
To read more, click here.
Merck‘s head of Global Clinical Development and Chief Medical Officer of Merck Research Laboratories, Dr. Roy Baynes, will retire from Merck in July. He has been succeeded by Dr. Eliav Barr, effective April 1.
Baynes will continue to report to Dr. Dean Y. Li, president, Merck Research Laboratories, until his retirement.
During his more than two decades at Merck, Barr has held positions of increasing responsibility including leadership roles in oncology and infectious diseases clinical development. He oversaw the company’s Vaccines/Infectious Disease area during a time when novel therapies for chronic hepatitis C and HIV-1 infections were developed. Most recently, he led MRL’s Global Medical Affairs organization from 2018 to January 2022, significantly expanding Merck’s scientific engagement and implementation efforts in oncology, vaccines and more. For more information, click here.
Reaction Biology, an industry leading provider of drug discovery services, has appointed Richard Kollender to the positions of CFO, CBO, and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the company’s next stage of growth. For more information, click here.
Etcembly has appointed Scott Cuthill PhD as Chief Business Officer. The Oxford-based company is harnessing the power of the adaptive immune system to transform the precision, scale and speed of development of TCR immunotherapies.
Cuthill previously worked in a senior business development role with Finland-based Valo Therapeutics. Prior to that he worked for Chroma Therapeutics and Ipsen Biopharma. For more information, click here.
Immunovia has appointed Jeff Borcherding as CEO of its U.S. subsidiary Immunovia, Inc. He joins from Myriad Genetics, one of the leading diagnostic companies in the U.S., where he was Chief Marketing Officer. Borcherding will be part of the Immunovia group management team from April 11. For more information, click here.
Olatec Therapeutics, a leader in the developing class of selective NLRP3 inhibitors, has named pharma industry veteran Mustafa Noor, MD as Chief Medical Officer, following the decision of current CMO, Dr. Curt Scribner, to retire from the position. For more information, click here.
Mesoblast, a company developing allogeneic cellular medicines for inflammatory diseases, has announced that Philip Krause MD has joined its Board of Directors.
Krause was, for the past decade, Deputy Director, Office of Vaccines Research and Review at the FDA’s Center for Biologics Evaluation and Research. He is currently Chair of the World Health Organization Covid Vaccines Research Expert Group, and most recently he shared responsibility for regulatory authorizations of Covid-19 vaccines in the U.S. For more information, click here.
CareFirst BlueCross BlueShield has appointed board-certified family physician Djinge Lindsay MD as its new Director of Public Health.
In this new role, Lindsay will lead a new Public Health infrastructure team focused on improving health outcomes and health equity in all aspects of the healthcare experience. By leveraging its data to understand where health disparities exist, and what factors, such as social determinants of health, are driving those disparities, the company can implement actionable and tailored responses for our members and communities. CareFirst will serve as a proactive partner with local health organizations, health departments, academic institutions and employers to develop strategies across all industries to better serve people throughout the region and meaningfully impact accessibility, affordability and quality of care for all. For more information, click here.
SyncThink, a next gen neurotechnology company and developer of the award-winning EYE-SYNC technology, announces today the expansion of its clinical advisory board and the creation of a specific advisory panel of Physical Therapy providers, to assist the company with growing product demand and market opportunities.
They include:
- Erin Isanhart
- Thomas Pianta
- Bobby Jean Lee
- Chelsea Ortega
They will work closely with the company to create awareness within the physical therapy profession, support new product development efforts, and serve as ambassadors to other providers in healthcare and sports. These new physical therapy advisers will join current advisers and physical therapists Lenore Herget of Massachusetts General Hospital and Marie Boo of the United States Women’s National Soccer Team.
For more information, click here.
binx health, a health tech and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, has appointed Todd Bennett as Chief Commercial Officer. Bennett has held multiple executive leadership roles at high-growth companies such as Luminex, Immucor, Roche and Abbott. For more information, click here.
eHealth Technologies has made two executive hires:
- Dan Torrens has been named CEO and succeeds Jeff Markin, who will remain in an advisory role. Torrens most recently served as chief operating officer for ConnectiveRx.
- Sean Ways, previously with the CMMI Institute, has been named Vice President of Engineering.
- Jeff Freier was promoted to Vice President of Operations.
Photo: marchmeena29, Getty Images
